Syncona Share News (SYNC)

IN BRIEF: Syncona's portfolio Achilles Therapeutics net loss narrows

Syncona Ltd - Healthcare company focused on developing its life science portfolio - Notes its portfolio company Archilles Therapeutics PLC's net loss in its second quarter ended June 30 narrows 2.9% to USD16.8 million, from USD17.3 million year-on-year. Cash and cash equivalents are "strong", standing at USD143.7 million on June 30, down 17% from USD173.3 million on December 31. Research & development expenses increase are USD13.8 million, down 6.8% from USD14.8 million at the same point the year prior. Archilles Therapeutics's general & administrative expenses were USD4.3 million, down 26% from USD5.8 million the year before, driven by a change in cost allocations and lower professional fees.

UK shareholder meetings calendar - next 7 days

Syncona net asset value falls as cites economic uncertainty, inflation

(Alliance News) - Syncona Ltd on Thursday reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies, citing inflation and economic uncertainty.

LONDON BRIEFING: Stocks set lower after US Fed decision, ahead of ECB

(Alliance News) - Stocks in London were set to open lower on Thursday, after the US Federal Reserve paused its interest rate hikes but indicated that more will follow this year.

Syncona annual NAV falls in tough macro conditions

(Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially offset by foreign exchange tailwinds and uplifts elsewhere in its portfolio.

Syncona launches new gene therapy company with GBP96 million funding

(Alliance News) - Syncona Ltd on Monday said it launched Beacon Therapeutics Holdings Ltd, a new ophthalmic therapy company, to treat patients with retinal diseases.

Syncona launches retinal disease-focussed Beacon Therapeutics

(Sharecast News) - Healthcare company developer and investor Syncona announced the launch of Beacon Therapeutics on Monday.

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd.

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Syncona investee Freeline swings to first-quarter profit

Syncona Ltd - London-based investor in healthcare companies - Reports first-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline is a clinical-stage biotechnology company. Freeline swings to a pretax profit of USD1.2 million in the first quarter of 2023, from a pretax loss of USD27.0 million last year. Profit is boosted by a reduction in expenses. Research & development expenses narrow to USD11.0 million from USD20.0 million, and total operating expenses similarly decrease to USD20.1 million from USD28.1 million.

Syncona say portfolio clinical company Achilles have widened losses

(Alliance News) - Syncona Ltd on Wednesday said that its portfolio company Achilles Therapeutics PLC has made losses in the first quarter of 2023, with cash equivalents falling and expenses increasing.

IN BRIEF: Syncona leads GBP22.5 million financing in Mosaic

Syncona Ltd - healthcare company focused on a portfolio of global leaders in life science - Leads GBP22.5 million Series A financing in Mosaic Therapeutics, a Cambridge England-based oncology therapeutics company. Commits GBP16.5 million alongside investment from Cambridge Innovation Capital. Reports holding value in Mosaic is GBP7.3 million following the investment of the first tranche of the Series A commitment and, once all current commitments are invested, will have a 52.8% stake in the business. Mosaic becomes Syncona's 13th company in its current portfolio.

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Syncona said direct exposure to SVB 'de minimis'

(Sharecast News) - Life sciences investor Syncona said it had a minimal exposure to the collapsed Silicon Valley Bank.